Soluções API

Dr. Reddy's API business supplies high-quality, affordable APIs to leading generic formulations manufacturers and is the preferred API partner for pharma companies in more than 100 countries.

R&D

Dr. Reddy’s supplies generic APIs to 80+ countries, excelling in R\&D across niche molecules and key therapies, with capabilities from lab to production in contained/non-contained APIs and advanced chemical processes.

Livro Branco

Dr. Reddy’s offers insightful whitepapers sharing expertise on APIs, formulations, regulatory trends, and industry innovations, helping global pharma partners gain knowledge, solve challenges, and drive faster, compliant product development.

DCAT Week 2026

Join us to discuss how we can solve your API challenges

Meet us at Suite: #1123, #1125 & #1126

23-26 March 2026
LOTTE New York Palace Hotel, 455 Madison Avenue (Madison at 50th Street), New York, NY 10022

Phone

Our Team at DCAT Week 2026

Deepak Sapra

CEO, Pharmaceutical Services and Active Ingredients

Dr. NM Sekhar

Vice President, API R&D

E Sreedhar

Executive Vice President, Global Regulatory Affairs

R Lalitha Kumari

Global Head of API Product Management & Head of Sales - US & Canada

Kalpesh Modi

Vice President, and Head – EU Market, API & B2B Collaborations

Juli Asmonga

Associate Vice President - Business Development, PSAI, North America

Ashish Rana

Regional Head, API, US & Canada

Dileep Kumar

API Sales and Marketing, North America

Rohan kaushik

Head, BD & Portfolio Management

About Dr.Reddy's API Business

We specialise in manufacturing and supplying a wide range of APIs for generic formulation manufacturers in India and overseas. The company has a diversified portfolio of 250+ active pharmaceutical ingredients, which are used in major therapeutic areas such as gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Our API manufacturing facilities adhere to cGMP (ICH Q7) and are inspected on a regular basis by international regulatory bodies. We have eight commercially inspected USFDA production plants, six in India and one each in Mexico and the United Kingdom.

Dr. Reddy’s API business operates in a number of global markets, including the United States of America, Latin America, Europe, India, Russia, and other CIS nations.

250+ APIs
8 Manufacturing sites
1970+ drug master files across global markets.
Over 325 ANDAs
Filed4500+ patents globally, out of which 1125 have been granted.
Experience with complex APIs and formulations supporting early market entries
Preferred pharma API supplier for pharma companies in more than 80 countries

Sustainability is deeply embedded in our purpose and forms the core of our organization.

Our journey began with APIs in 1984, and we evolved from small molecules to large molecules and from APIs to finished formulations over the decades. Amidst this evolution, what has remained constant at the heart of our organization is a deep commitment to patients and the customers we serve through our core principles of collaboration and sustainability. By the end of FY2025, we had served over 756 million patients and continue our endeavours to reach over 1.5 billion patients globally by 2030. This means almost one in every five people on this planet will use Dr. Reddy’s product or service. The health of people is strongly linked to the health of our planet. That's why our integrated report also shows how sustainability and business are strongly linked.

Our ESG (Environment, Social & Governance) Goal:

Building the future responsibly

Our ESG goals are deeply embedded in our business strategy, guiding our efforts to create a significant and lasting positive impact on the planet and its people. We have made fair progress across several of these goals, even as a few continue to present challenges. We are committed to advancing our ESG journey, ensuring that as we prosper, we do so responsibly and with resilience.

What we achieved in the past year:

3.8

Bn total revenue (17% growth)

165

New products launched

111

DMFs filed, (1,630+ Cumulative DMFs)

249

Dossiers, including 10 ANDAs filed

76

Filings in the US pending for approval

20.4%

Women in leadership

96%

Employees trained for skill upgradation

0.14 to 0.07

*LTIFR reduced from

126

Differently abled employees

700,000+

Lives impacted through CSR

783

Million KL of water saved through agri-water saving techniques

66,723

MTCO2e of direct emissions reduction

11%

Reduction in water intensity per rupee of turnover with respect to FY2024

60%

Carbon neutrality achieved

75,761

KL of harvested rainwater used

54%

Water reused/recycled

Our Plants

Dr. Reddy’s Participation at DCAT Week 2026

DCAT Week 2026 is one of the most prominent annual gatherings for the global pharmaceutical and chemical manufacturing community. For Dr. Reddy’s Laboratories, it serves as a strategic platform to strengthen engagement with global partners, highlight capabilities, and reinforce its leadership in the API (Active Pharmaceutical Ingredients) space.

At DCAT, our API business plays a central role in showcasing Dr. Reddy’s end‑to‑end strengths—from a broad product portfolio and high-quality manufacturing to our commitment to sustainability and innovation across the value chain. The event enables our teams to conduct focused meetings with customers, suppliers, and industry collaborators to drive long‑term business growth.

What Dr. Reddy’s Does at DCAT Week 2026

Showcases a Robust API Portfolio
We present our extensive offering of 250+ high‑quality APIs across key therapeutic areas including oncology, cardiovascular, gastrointestinal, central nervous system, and anti-infectives. This demonstrates our capability to support diverse customer requirements globally.
Engages with Global Stakeholders
DCAT provides a forum for our commercial, sourcing, and leadership teams to interact with existing partners and explore new collaborations. These discussions often translate into strategic supply agreements and long-term business partnerships.
Drives Opportunities for Growth & Collaboration
Our teams use DCAT to identify emerging market needs, exchange insights on industry trends, and explore avenues for co-development, technology partnerships, and portfolio expansion.
Highlights Our Sustainability Vision
We take the opportunity to communicate our strong ESG performance, responsible manufacturing practices, and initiatives aimed at reducing environmental impact—reinforcing our commitment to a sustainable and resilient pharmaceutical supply chain.

Key Takeaways

DCAT Week is a high-impact platform for networking, strategic discussions, and business development within the pharmaceutical and chemical supply ecosystem.
Dr. Reddy’s API division leverages the event to strengthen relationships, showcase technical expertise, and drive growth in global API markets.
Our participation reflects a clear commitment to quality, innovation, operational excellence, and meaningful collaborations that support customers across the world.